<DOC>
	<DOCNO>NCT00530777</DOCNO>
	<brief_summary>In study , determine whether treat pregnant breastfeed woman co-infected human immunodeficiency virus type 1 ( HIV-1 ) herpes simplex virus type 2 ( HSV-2 ) daily valacyclovir reduce HIV-1 level plasma , genital , breast milk decrease risk mother-to-child HIV-1 transmission .</brief_summary>
	<brief_title>HSV-2 Suppression Reduce Maternal HIV-1 RNA Levels During Pregnancy Breastfeeding</brief_title>
	<detailed_description>Each year 500,000 child become HIV-1-infected sub-Saharan Africa exposure maternal virus blood , genital secretion , breast milk . Identifying feasible , safe , affordable intervention prevent mother-to-child transmission remain priority HIV-1 prevention research . Interventions reduce breast milk HIV-1 transmission lack urgently need . We propose randomized clinical trial determine whether incorporate HSV-2 suppression valacyclovir standard prevention mother-to-child HIV-1 transmission regimens reduce plasma , cervical , breast milk HIV-1 RNA level risk transmission among HIV-1-infected HSV-2-seropositive woman . We plan enroll total 148 HIV-1 HSV-2 co-infected pregnant woman CD4 &gt; 200 cells/μl seek antenatal care prior 32 week gestation clinic Nairobi , Kenya . Women randomize receive either valacyclovir suppressive therapy placebo 34 week gestation mother-infant pair follow 12 month postpartum . Follow-up visit schedule 38 week gestation ; birth ; 2 , 6 , 10 14 week ; 6 , 9 , 12 month postpartum . Maternal blood , genital , breast milk specimen obtain follow-up visit use determine effect valacyclovir suppressive therapy plasma breast milk HIV-1 RNA level . Infant filter paper specimens HIV-1 DNA assay collect birth ; 2 , 6 , 10 14 week ; 6 , 9 , 12 month order compare proportion infant acquire HIV-1 12 month two study arm determine time HIV-1 infection . In addition , monitor maternal infant renal function preparation large randomized clinical trial Africa . The result study help guide design multi-site clinical trial adequate power determine effect HSV-2 suppression vertical transmission HIV-1 infection .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Herpes Simplex</mesh_term>
	<mesh_term>Valacyclovir</mesh_term>
	<mesh_term>Acyclovir</mesh_term>
	<criteria>HIV1 seropositive HSV2 seropositive Plans deliver Nairobi Resides plan remain Nairobi 12 month postpartum 18 year age old CD4 count &gt; 250 cells/μl indication highly active antiretroviral therapy ( e.g. , WHO stage III IV ) hypersensitivity valacyclovir acyclovir</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Disease Transmission , Vertical</keyword>
	<keyword>valacyclovir</keyword>
	<keyword>Randomized Controlled Trials</keyword>
	<keyword>HIV</keyword>
	<keyword>herpes</keyword>
	<keyword>Herpesvirus 2 , Human</keyword>
	<keyword>HIV Seronegativity</keyword>
</DOC>